LETTER: African vaccine firms need a shot in the arm
19 July 2023 - 17:24
Support our award-winning journalism. The Premium package (digital only) is R30 for the first month and thereafter you pay R129 p/m now ad-free for all subscribers.
In Africa, 99% of all vaccines administered to people are imported. The consequences of this are notably concerning — and became painfully evident during Covid-19, when foreign vaccine manufacturers were able to control distribution based on their preferred commercial agreements.
Sadly, this is not the first time that Africa has been excluded from the latest developments in healthcare and vaccine technology. We will have to act quickly to prevent this happening again, by addressing our collective reliance on imports, with investment into our own pharmaceutical manufacturing industries now.
This undertaking is already being led by the Partnerships for African Vaccine Manufacturing Framework For Action (PAVM). The PAVM has already set itself an ambitious goal, aiming to ensure that 60% of Africa’s vaccine demand is supplied by its own vaccine-manufacturing industry by 2040.
If we are to meaningfully tackle this expansion, we need to empower players in the sector with the regulatory and financial support they require to become innovators, with sole control over the intellectual property of their products.
This support must remain in effect until there is a proven claim regarding the efficacy of the product being manufactured. Once manufacturers reach the regulatory space, we need to ensure that local authorities (that is, the SA Health Products Regulatory Authority) create an enabling environment with quick turnaround times for the registration of pharmaceuticals and biologics.
The public sector should also offer preferential treatment to local manufacturers in their public contracts and should consider duties on imports — perhaps restricting them altogether.
Government should consider offering exclusive rights to local manufacturers, based on the economic multiplier effect. Price preference must be weighed equally against the opportunity for job creation, skills development, improved health outcomes, investment, and overall economic growth.
The national government would also have to support local manufacturers with subsidies and sound offtake agreements, in an environment that is defined by a stable political economy to create the right climate for continued investment.
Providing private sector players with equity in exchange for their years of expertise and business acumen would contribute significantly to improving the operating environment of any healthcare manufacturer in Africa as well.
Michael Mynhardt Business strategist and group executive Via email
Support our award-winning journalism. The Premium package (digital only) is R30 for the first month and thereafter you pay R129 p/m now ad-free for all subscribers.
LETTER: African vaccine firms need a shot in the arm
In Africa, 99% of all vaccines administered to people are imported. The consequences of this are notably concerning — and became painfully evident during Covid-19, when foreign vaccine manufacturers were able to control distribution based on their preferred commercial agreements.
Sadly, this is not the first time that Africa has been excluded from the latest developments in healthcare and vaccine technology. We will have to act quickly to prevent this happening again, by addressing our collective reliance on imports, with investment into our own pharmaceutical manufacturing industries now.
This undertaking is already being led by the Partnerships for African Vaccine Manufacturing Framework For Action (PAVM). The PAVM has already set itself an ambitious goal, aiming to ensure that 60% of Africa’s vaccine demand is supplied by its own vaccine-manufacturing industry by 2040.
If we are to meaningfully tackle this expansion, we need to empower players in the sector with the regulatory and financial support they require to become innovators, with sole control over the intellectual property of their products.
This support must remain in effect until there is a proven claim regarding the efficacy of the product being manufactured. Once manufacturers reach the regulatory space, we need to ensure that local authorities (that is, the SA Health Products Regulatory Authority) create an enabling environment with quick turnaround times for the registration of pharmaceuticals and biologics.
The public sector should also offer preferential treatment to local manufacturers in their public contracts and should consider duties on imports — perhaps restricting them altogether.
Government should consider offering exclusive rights to local manufacturers, based on the economic multiplier effect. Price preference must be weighed equally against the opportunity for job creation, skills development, improved health outcomes, investment, and overall economic growth.
The national government would also have to support local manufacturers with subsidies and sound offtake agreements, in an environment that is defined by a stable political economy to create the right climate for continued investment.
Providing private sector players with equity in exchange for their years of expertise and business acumen would contribute significantly to improving the operating environment of any healthcare manufacturer in Africa as well.
Michael Mynhardt
Business strategist and group executive
Via email
Invest in African vaccine producers to mitigate risk of future pandemics, says Biovac
Inside SA’s mRNA hub: What it looks like and how it works
ANN CROTTY: Conspiracy theories and a new Kennedy presidential hopeful
Gavi says nine more African states to receive malaria vaccines
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
Most Read
Related Articles
JOSHUA NOTT: UK would benefit from taking bold bets on Africa
Gavi says nine more African states to receive malaria vaccines
Cyril Ramaphosa lays into the West in Paris for vaccine inequality
Published by Arena Holdings and distributed with the Financial Mail on the last Thursday of every month except December and January.